FDA Approves Evkeeza for Rare High Cholesterol in Children
FDA has expanded Evkeeza (evinacumab-dgnb) to children aged 1 to under 5 with homozygous familial hypercholesterolemia, completing a stepwise...
Jon Napitupulu
PrestoDoctor Expands Cannabis Telehealth to Connecticut
PrestoDoctor, a telemedicine platform focused on medical cannabis evaluations and a subsidiary of Dogecoin Cash, has expanded into Connecticut,...
Strategic Partnership to Accelerate Immunotherapy Innovation
OSE Immunotherapeutics has entered a strategic partnership with Inserm Transfert and Nantes University to source, mature, and industrialize early-stage...
Organogenesis Provides Update on Phase 3 Renu® Study
Organogenesis reported that its second Phase 3 randomized controlled trial of ReNu, a cryopreserved amniotic suspension allograft for symptomatic...
Kraig Labs Expands Production for Large International Order
Kraig Biocraft Laboratories has opened a second Southeast Asian rearing center for its engineered silkworms, bringing parallel production online...
BioXcel Therapeutics Announces Positive Topline Results from Phase 3 SERENITY Trial of BXCL501
BioXcel Therapeutics reported that its pivotal Phase 3 SERENITY at-home study met its primary endpoint, demonstrating that a 120...
Quell Therapeutics Forms World-Class Scientific Advisory Board
Quell Therapeutics has convened a new scientific advisory board to steer its engineered T-regulatory cell therapy portfolio, adding heavyweight...
Seres Therapeutics at H.C. Wainwright 27th Annual Global Investment Conference
Seres Therapeutics will present a company overview at the H.C. Wainwright Global Investment Conference in New York on September...
Mesoblast Reports Mixed Financial Results, Corporate Update Webcast
Mesoblast will host a webcast to review operational highlights and full-year results for the period ended June 30, 2025,...
Medicinova Completes COMBAT-ALS Trial Enrollment
MediciNova has completed target enrollment in COMBAT-ALS, its Phase 2b/3 clinical trial of MN-166 (ibudilast), across sites in the...